Connection
Christopher Porter to Neoplasm Proteins
This is a "connection" page, showing publications Christopher Porter has written about Neoplasm Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.564 |
|
|
|
-
Porter CC. Germ line mutations associated with leukemias. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):302-308.
Score: 0.426
-
Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget. 2016 Mar 29; 7(13):15757-71.
Score: 0.102
-
Zoine JT, Prince C, Story JY, Branella GM, Lytle AM, Fedanov A, Alexander JS, Porter CC, Doering CB, Spencer HT, Chandrakasan S. Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells. Gene Ther. 2022 05; 29(5):1-12.
Score: 0.037